Table 6 Number, treatment duration, total payers’ cost, and total patients’ OOP cost per treatment regimen

From: Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection

Treatment regimen Patients, n (%) Mean treatment duration (months) Total cost (payers) [$] Total OOP cost (patients) [$] Patients with OOP cost ≥ 10,000 (n)
Mean SD Median Mean SD Median Patients with zero OOP cost, n (%)
Full cohort           
 Dual therapy 1514 (20.4) 6.3 21,372* 9830 19,072 601 1396 304 154 (10.2%) 4
 1DAA triple 1830 (24.7) 6.4 74,631* 21,904 77,603 811 1749 448 179 (9.8%) 12
 2DAA triple 181 (2.4) 3.1 101,715* 15,597 102,946 733 1.782 292 28 (15.5%) 1
 All-oral DAA 3882 (52.4) 3.0 99,876* 47,006 92,836 933 6143 125 906 (23.3%) 59
HCV only           
 Dual therapy 1469 (20.3) 6.3 21,262 9761 19,041 607 1416 302 149 (10.1%) 4
 1DAA triple 1809 (25.1) 6.4 74,384 21,657 77,495 812 1758 447 176 (9.7%) 12
 2DAA triple 174 (2.4) 3.1 101,508 15,661 103,016 750 1815 292 27 (15.5%) 1
 All-oral DAA 3768 (52.2) 3.0 99,985 47,251 92,833 953 6233 125 878 (23.3%) 59
HCV/HIV           
 Dual therapy 45 (24.1) 7.4 24,982 11,411 21,237 399 303 338 5 (11.1%) 0
 1DAA triple 21 (11.2) 7.8 95,877 31,590 97,191 672 603 473 3 (14.3%) 0
 2DAA triple 7 (3.7) 3.1 106,850 13,938 102,335 322 286 226 1 (14.3%) 0
 All-oral DAA 114 (61.0) 2.9 96,303 38,022 92,886 264 659 108 28 (24.6%) 0
  1. 1DAA first-generation direct-acting antivirals, 2DAA second-generation direct-acting antivirals, OOP out-of-pocket, SD standard deviation
  2. *Kruskal–Wallis test for difference in mean total cost (payers), full cohort: p < 0.001
  3. Kruskal–Wallis test for difference in mean OOP cost (patients), full cohort: p < 0.001
  4. Kruskal–Wallis test for difference in mean total cost (payers), HCV only versus HCV/HIV: p = 0.094
  5. Kruskal–Wallis test for difference in mean OOP cost (patients), HCV only versus HCV/HIV: p = 0.023